Litigation Details for Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-27
Court	District Court, D. Delaware	Date Terminated	2017-03-31
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,794,410; 9,186,346
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-27				External link to document
2016-12-26	17		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 …2016 31 March 2017 1:16-cv-01311 830 Patent None District Court, D. Delaware	External link to document
2016-12-26	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 …2016 31 March 2017 1:16-cv-01311 830 Patent None District Court, D. Delaware	External link to document

Sanofi-Aventis U.S. LLC v. Accord Healthcare: Jevtana Patent Litigation Summary, 1:16-cv-01311

Last updated: October 19, 2026

Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., No. 1:16-cv-01311-RGA, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware concerning Accord’s abbreviated new drug application for generic cabazitaxel, the active ingredient in Sanofi’s Jevtana product. The dispute focused on Sanofi’s cabazitaxel formulation patent estate, particularly U.S. Patent No. 8,927,592.

The case was part of Sanofi’s broader defense of Jevtana against generic injectable-drug manufacturers. The public docket indicates that the matter was resolved without a reported merits opinion establishing invalidity or noninfringement against Accord.

What drug and product were at issue in Sanofi v. Accord?

The case involved Jevtana, an intravenous cabazitaxel product marketed by Sanofi.

Item	Detail
Branded product	Jevtana
Active ingredient	Cabazitaxel
Dosage form	Injectable concentrate requiring dilution before intravenous administration
Sponsor	Sanofi-Aventis U.S. LLC
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01311-RGA
Filing period	2016
Presiding judge	Richard G. Andrews
Defendant	Accord Healthcare, Inc.
Principal patent at issue	U.S. Patent No. 8,927,592

Jevtana was approved by the FDA for treatment of metastatic castration-resistant prostate cancer in patients previously treated with a docetaxel-containing regimen. The formulation contains cabazitaxel with excipients including polysorbate 80, ethanol and water.

What patents protected Jevtana in the Accord litigation?

The central patent associated with the Jevtana formulation litigation was U.S. Patent No. 8,927,592.

U.S. Patent No. 8,927,592

Field	Detail
Patent number	8,927,592
Patent owner or asserting party	Sanofi-Aventis U.S. LLC and related Sanofi entities
General subject matter	Pharmaceutical compositions containing cabazitaxel
Product relevance	Jevtana injectable formulation
Issue date	January 6, 2015
Listed expiration	April 7, 2030, subject to applicable patent-term adjustments or extensions
Patent category	Formulation and composition patent

The patent claims were directed to pharmaceutical compositions containing cabazitaxel in a solvent system designed to provide a stable injectable formulation. The formulation patent was commercially important because cabazitaxel itself was not the only barrier to generic competition. A generic manufacturer also had to address the branded product’s specific concentration, excipient system, stability profile and administration characteristics.

Sanofi also held related cabazitaxel patent rights, including U.S. Patent No. 9,266,951. The patents asserted against individual ANDA applicants varied by case and filing date. The public record for the Accord action is principally associated with the ‘592 patent.

What was the legal basis for Sanofi’s lawsuit?

Sanofi filed the action after receiving notice of Accord’s Paragraph IV certification.

Under the Hatch-Waxman framework, an ANDA applicant may certify that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. A Paragraph IV certification gives the patent holder a basis to sue for infringement before FDA approval of the ANDA.

Sanofi’s complaint alleged that Accord’s proposed cabazitaxel product would infringe one or more claims of Sanofi’s Jevtana formulation patent. The filing of the action triggered the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the case was resolved earlier or the stay was otherwise terminated.

The core issues were expected to include:

• Whether Accord’s proposed formulation fell within the asserted patent claims.
• Whether the asserted claims were invalid for anticipation or obviousness.
• Whether the patent claims were enabled and adequately described.
• Whether Sanofi had complied with Orange Book and Hatch-Waxman requirements.
• Whether Accord’s proposed product could launch before the patent’s listed expiration.

Was Accord’s Paragraph IV challenge successful?

The public record does not establish a litigated judgment holding the asserted Sanofi patent invalid or not infringed by Accord.

The Accord action appears to have been resolved by agreement or dismissal rather than by a published district court decision addressing the full merits of the patent claims. No reported opinion from the action establishes that Accord defeated the ‘592 patent on invalidity, unenforceability or noninfringement grounds.

That distinction matters. A dismissal or settlement does not provide the same commercial or precedential result as a judgment after trial. It generally leaves the patent’s formal validity and enforceability intact unless the settlement expressly provides otherwise.

What was the litigation status and outcome?

The action was resolved without a reported trial verdict against Sanofi.

Litigation issue	Publicly established result
Filing	Sanofi sued Accord in the District of Delaware in 2016
Patent dispute	Jevtana cabazitaxel formulation rights
Paragraph IV context	Yes
Trial judgment	No reported merits judgment against Accord
Published claim-construction ruling	No controlling published ruling identified for this action
Invalidity finding	None publicly established
Noninfringement finding	None publicly established
Settlement or dismissal	The docket reflects resolution without a reported merits opinion
Settlement terms	Not publicly disclosed in the available record

Sanofi’s broader Jevtana litigation against other generic manufacturers produced separate proceedings and should not be conflated with the Accord docket. Outcomes in related defendants’ cases do not automatically determine Accord’s rights because the ANDA products, defenses, settlement terms and procedural postures may differ.

What is the Orange Book status of Jevtana?

Jevtana’s Orange Book protection was based primarily on formulation patents rather than a simple active-ingredient patent.

The relevant commercial protection included:

1. The cabazitaxel formulation patent estate.
2. FDA-listed patent rights associated with Jevtana.
3. Regulatory exclusivity associated with the approved product and indication.
4. Potential pediatric exclusivity, if granted and applicable to the relevant listings.

The key listed patent associated with the formulation dispute was U.S. Patent No. 8,927,592, with an April 7, 2030 expiration date before any applicable six-month pediatric extension. Orange Book listing details can change through patent-listing updates, delistings, patent-term adjustments and FDA administrative determinations. A patent’s Orange Book listing does not itself establish infringement or validity.

When does Jevtana lose exclusivity?

The principal patent-based barrier identified in the Accord litigation was scheduled to run through April 7, 2030.

That date does not necessarily equal the earliest possible generic launch date. Generic entry can occur before patent expiration through:

• A negotiated settlement date.
• A license or covenant not to sue.
• A court judgment of invalidity or noninfringement.
• A successful patent challenge by another ANDA applicant.
• A change in the Orange Book listing.
• A regulatory pathway that does not infringe the listed claims.

Conversely, pediatric exclusivity or other enforceable rights may extend the effective barrier beyond the nominal patent expiration date.

What formulation protections create generic entry risk?

The Jevtana case illustrates why injectable oncology products can retain meaningful patent protection after basic composition-of-matter rights have expired.

Concentration and excipient risk

Cabazitaxel formulations must address solubility, stability and administration requirements. A generic manufacturer may design around a claim by changing:

• The concentration of cabazitaxel.
• The ratio of solvent components.
• The use or amount of polysorbate 80.
• The dilution procedure.
• The container or delivery system.
• The storage conditions.
• The product’s reconstitution or infusion instructions.

Each design change can create a separate regulatory and technical issue. A formulation that avoids literal infringement may still face a doctrine-of-equivalents argument, although the scope of that doctrine depends on the patent claims and prosecution history.

Manufacturing barriers

For injectable products, manufacturing risk includes:

• Sterility assurance.
• Particulate control.
• Container-closure compatibility.
• Stability during storage and shipment.
• Consistency of active-drug concentration.
• Compatibility with infusion materials.
• Scale-up and validation of the commercial process.

These issues do not independently create patent exclusivity, but they can delay approval or increase launch costs. They also make a formulation patent more commercially relevant than a narrow tablet-process patent.

How strong was Sanofi’s Jevtana patent estate?

Sanofi’s estate had meaningful commercial strength because it targeted the finished injectable formulation rather than only the cabazitaxel molecule.

Strength factor	Assessment
Product coverage	Directly linked to the approved injectable product
Remaining term in the litigation period	More than a decade
Technical barrier	Injectable formulation, stability and solvent-system requirements
Design-around potential	Moderate; dependent on formulation chemistry
Litigation leverage	High enough to support pre-approval ANDA litigation
Public merits precedent from Accord case	Limited
Settlement transparency	Low because commercial terms were not publicly disclosed

The estate’s strength should not be measured only by patent expiration. The relevant commercial question is whether a generic applicant can obtain approval for a product that both satisfies FDA requirements and avoids the listed claim scope.

Which companies challenged Jevtana exclusivity?

Sanofi faced Jevtana-related generic competition from multiple manufacturers in separate actions. Participants in the broader cabazitaxel litigation landscape included Accord and other generic or injectable-drug companies.

Each defendant’s risk profile differed based on:

• The ANDA formulation.
• The Paragraph IV certification.
• The asserted patent claims.
• The defendant’s manufacturing process.
• The settlement date.
• Any authorized-generic or license arrangement.

A settlement with one ANDA applicant does not necessarily authorize all competing applicants to launch.

What does the case mean for generic launch scenarios?

The Accord case supports three principal launch scenarios.

Settlement launch

The most likely resolution in a Hatch-Waxman formulation case is a confidential settlement providing a permitted launch date before patent expiration. The settlement may include a license, supply arrangement, authorized generic provision or other commercial restrictions.

Patent litigation victory

Accord could have launched before the listed expiration if it obtained a final judgment that the asserted patent claims were invalid, unenforceable or not infringed. No such reported judgment is established for this case.

Post-expiration launch

Absent a license or favorable judgment, a generic product directed to the listed formulation patent would face a material risk of injunction or damages for an early launch.

Did the case involve biosimilar risk?

No. The case was an ANDA case involving a small-molecule injectable drug, not a biosimilar action under the Biologics Price Competition and Innovation Act.

Cabazitaxel is regulated as a drug for this purpose. The litigation therefore involved Paragraph IV patent certification, ANDA approval and the Hatch-Waxman statutory stay. It did not involve a biologics license application, a biosimilar abbreviated pathway or the patent dance under the BPCIA.

What is the commercial significance for Sanofi?

Jevtana generated revenue from oncology treatment before generic cabazitaxel competition expanded. A successful generic launch would affect:

• Sanofi’s branded cabazitaxel revenue.
• Hospital and oncology-practice purchasing.
• Net pricing and contracting.
• Sanofi’s manufacturing utilization.
• Reimbursement economics for prostate-cancer treatment.
• Competitive positioning against other taxane-based therapies.

The revenue exposure was concentrated in the cabazitaxel franchise rather than Sanofi’s broader portfolio. Because Jevtana is an injectable oncology product, generic substitution may be slower and more account-specific than substitution for an oral solid dose product. That does not eliminate price erosion once multiple approved suppliers enter.

Key Takeaways

• Sanofi-Aventis U.S. LLC v. Accord Healthcare, No. 1:16-cv-01311-RGA, was a Delaware Hatch-Waxman action involving generic cabazitaxel.
• The branded reference product was Jevtana.
• The principal patent associated with the dispute was U.S. Patent No. 8,927,592.
• The patent covered a cabazitaxel injectable formulation and was listed to expire on April 7, 2030.
• The action was resolved without a reported merits judgment establishing invalidity or noninfringement against Accord.
• Publicly available information does not disclose the material commercial terms of any resolution.
• The case involved an ANDA Paragraph IV challenge, not a biosimilar proceeding.
• The primary generic-entry risk came from formulation design-around and settlement timing rather than from a public invalidity ruling.

FAQs

What was the Sanofi v. Accord case number?

The case number was 1:16-cv-01311-RGA in the U.S. District Court for the District of Delaware.

Which Sanofi drug was involved in the lawsuit?

The lawsuit involved Jevtana, Sanofi’s cabazitaxel injectable product for metastatic castration-resistant prostate cancer.

What was the key Jevtana patent?

The key patent associated with the action was U.S. Patent No. 8,927,592, directed to cabazitaxel pharmaceutical compositions.

Did Accord launch generic Jevtana before the patent expiration date?

The public docket does not establish an early launch right or a merits judgment authorizing Accord to launch before the listed patent expiration.

Is Sanofi v. Accord relevant to biosimilar litigation?

No. It was a small-molecule ANDA case governed by the Hatch-Waxman Act, not a BPCIA biosimilar case.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., No. 1:16-cv-01311-RGA (D. Del. filed 2016).

3. U.S. Patent No. 8,927,592. (2015). Pharmaceutical compositions comprising cabazitaxel.

4. U.S. Patent No. 9,266,951. (2016). Pharmaceutical compositions comprising cabazitaxel.

5. U.S. Food and Drug Administration. (2010). Jevtana (cabazitaxel) prescribing information. Avaliable at FDA Drugs@FDA.